早些时候报道，ImmunityBio获得了ANKTIVA在英国的营销许可，该公司使用Calmette-Guérin杆菌治疗膀胱癌，将突破性疗法扩展到美国以外

2025-07-08 14:29

ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, helping eliminate cancer
Already approved in the U.S. and designated as a Breakthrough Therapy by the FDA, this marks ANKTIVA's first marketing approval outside the U.S.
ANKTIVA plus BCG offers a new option for eligible patients among the 16,400 to 18,000 people diagnosed with NMIBC in the UK each year